Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function

Journal of Immunology

Volumn 172, Issue 12, 2004, Pages 7510-7518

  Flowers, Lawrence O ^a   Johnson, Howard M ^a   Mujtaba, Mustafa G ^a   Ellis, Morgan R ^a   Haider, S Mohammed I ^a   Subramaniam, Prem S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERYTHROPOIETIN RECEPTOR; GAMMA INTERFERON; JANUS KINASE 2; JANUS KINASE 2 PEPTIDE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE SRC; REGULATOR PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; SYNTHETIC PEPTIDE; TRYPTOPHYLLEUCYLVALYLPHENYLALANYLPHENYLALANYLISOLEUCYLPHENYLALANYLTYROSYLPH ENYLALANYLPHENYLALANYLARGININE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; DRUG EFFECT; ENZYME REGULATION; HOMEOSTASIS; MOUSE; NONHUMAN; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 2942615015     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.12.7510     Document Type: Article

References (33)

1. Blume-Jensen, P., and T. Hunter. 2001. Oncogenic kinase signalling. Nature 411:355.
2. Tsygankov, A. Y. 2003. Non-receptor tyrosine kinases. Front. Biosci. 8:S595.
3. Laird, A. D., and J. M. Cherrington. 2003. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin. Investig. Drugs 12:51.
4. Capdeville, R., E. Buchdunger, J. Zimmermann, and A. Matter. 2002. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1:493.
5. Kotenko, S. V., and S. Pestka. 2000. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 19:2557.
6. Hanada, T., I. Kinjyo, K. Inagaki-Ohara, and A. Yoshimura. 2003. Negative regulation of cytokine signaling by CIS/SOCS family proteins and their roles in inflammatory diseases. Rev. Physiol. Biochem. Pharmacol. 149:72.
7. Kile, B. T., B. A. Schulman, W. S. Alexander, N. A. Nicola, H. M. Martin, and D. J. Hilton. 2002. The SOCS box: a tale of destruction and degradation. Trends Biochem. Sci. 27:235.
8. Alexander, W. S. 2002. Suppressors of cytokine signalling (SOCS) in the immune system. Nat. Rev. Immunol. 2:410.
9. Larsen, L., and C. Ropke. 2002. Suppressors of cytokine signalling: SOCS. APMIS 110:833.
10. Ritter, C. A., and C. L. Arteaga. 2003. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin. Oncol. 30(1 Suppl. 1):3.
11. Szente, B. E., I. J. Weiner, M. J. Jablonsky, N. R. Krishna, B. A. Torres, and H. M. Johnson. 1996. Structural requirements for agonist activity of a murine interferon-γ peptide. J. Interferon Cytokine Res. 16:813.
12. Familletti, P. C., S. Rubinstein, and S. Pestka. 1981. A convenient and rapid cytopathic effect inhibition assay for interferon. Methods Enzymol. 78:387.
13. Yasukawa, H., H. Misawa, H. Sakamoto, M. Masuhara, A. Sasaki, T. Wakioka, S. Ohtsuka, T. Imaizumi, T. Matsuda, J. N. Ihle, and A. Yoshimura. 1999. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18:1309.
14. Villain, M., P. L. Jackson, M. K. Manion, W. J. Dong, Z. Su, G. Fassina, T. M. Johnson, T. T. Sakai, N. R. Krishna, and J. E. Blalock. 2000. De novo design of peptides targeted to the EF hands of calmodulin. J. Biol. Chem. 275:2676.
15. Johnson, H. M., and B. A. Torres. 1988. A novel arginine vasopressin-binding peptide that blocks arginine vasopressin modulation of immune function. J. Immunol. 141:2420.
16. Fassina, G., G. Cassani, and A. Corti. 1992. Binding of human tumor necrosis factor a to multimeric complementary peptides. Arch. Biochem. Biophys. 296:137.
17. Blalock, J. E., and K. L. Bost. 1986. Binding of peptides that are specified by complementary RNAs. Biochem. J. 234:679.
18. Ferrara, N., H. P. Gerber, and J. LeCouter. 2003. The biology of VEGF and its receptors. Nat. Med. 9:669.
19. Xia, L., L. Wang, A. S. Chung, S. S. Ivanov, M. Y. Ling, A. M. Dragoi, A. Platt, T. M. Gilmer, X. Y. Fu, and Y. E. Chin. 2002. Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J. Biol. Chem. 277:30716.
20. Wells, A. 1999. EGF receptor. Int. J. Biochem. Cell Biol. 31:637.
21. Iwamoto, T., T. Senga, Y. Naito, S. Matsuda, Y. Miyake, A. Yoshimura, and M. Hamaguchi. 2000. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation. Oncogene 19:4795.
22. Starr, R., D. Metcalf, A. G. Elefanty, M. Brysha, T. A. Willson, N. A. Nicola, D. J. Hilton, and W. S. Alexander. 1998. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc. Natl. Acad. Sci. USA 95:14395.
23. Metcalf, D., W. S. Alexander, A. G. Elefanty, N. A. Nicola, D. J. Hilton, R. Starr, S. Mifsud, and L. Di Rago. 1998. Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1. Leukemia 13:926.
24. Marine, J. C., C. McKay, D. Wang, D. J. Topham, E. Parganas, H. Nakajima, H. Pendeville, H. Yasukawa, A. Sasaki, A. Yoshimura, and J. N. Ihle. 1999. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98:617.
25. Roberts, A. W., L. Robb, S. Rakar, L. Hartley, L. Cluse, N. A. Nicola, D. Metcalf, D. J. Hilton, and W. S. Alexander. 2001. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc. Natl. Acad. Sci. USA 98:9324.
26. Hortner, M., U. Nielsch, L. M. Mayr, P. C. Heinrich, and S. Haan. 2002. A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur. J. Biochem. 269:2516.
27. Kubo, M., T. Hanada, and A. Yoshimura. 2003. Suppressors of cytokine signaling and immunity. Nat. Immunol. 4:1169.
28. Peeters, P., S. D. Raynaud, J. Cools, I. Wlodarska, J. Grosgeorge, P. Philip, F. Monpoux, L. Van Rompaey, M. Baens, H. Van den Berghe, and P. Marynen. 1997. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9; 12) in a lymphoid and t(9; 15; 12) in a myeloid leukemia. Blood 90:2535.
29. Lacronique, V., A. Boureux, V. D. Valle, H. Poirel, C. T. Quang, M. Mauchauffe, C. Berthou, M. Lessard, R. Berger, J. Ghysdael, and O. A. Bernard. 1997. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:1309.
30. Ho, J. M., B. K. Beattie, J. A. Squire, D. A. Frank, and D. L. Barber. 1999. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 93:4354.
31. Monni, R., S. C. Santos, M. Mauchauffe, R. Berger, J. Ghysdael, F. Gouilleux, S. Gisselbrecht, O. Bernard, and V. Penard-Lacronique. 2001. The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells. Oncogene 20:849.
32. Ho, J. M., M. H. Nguyen, J. K. Dierov, K. M. Badger, B. K. Beattie, P. Tartaro, R. Haq, B. W. Zanke, M. P. Carroll, and D. L. Barber. 2002. TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood 100:1438.
33. Frantsve, J., J. Schwaller, D. W. Sternberg, J. Kutok, and D. G. Gilliland. 2001. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol. Cell. Biol. 21:3547.